Evidence map›Paper›PMID 38595983›Full record

ArticleMolecular therapy. Oncology2024

Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors.

Julia A Nikrad, Robert T Galvin, Mackenzie M Sheehy, Ethan L Novacek, Kari L Jacobsen, Stanislas M A S Corbière, Pauline J Beckmann, Tyler A Jubenville, Masato Yamamoto, David A Largaespada

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Julia A NikradDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Robert T GalvinDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Mackenzie M SheehyDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Ethan L NovacekDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Kari L JacobsenDepartment of Surgery, University of Minnesota, 516 Delaware Street SE, Minneapolis, MN 55455, USA.
Stanislas M A S CorbièreInstitute for Research in Immunology and Cancer, Université de Montréal, 2950 Chemin de Polytechnique Marcelle-Coutu Pavilion, Montréal, QC H3T1J4, Canada.
Pauline J BeckmannDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Tyler A JubenvilleDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
Masato YamamotoDepartment of Surgery, University of Minnesota, 516 Delaware Street SE, Minneapolis, MN 55455, USA.
David A LargaespadaDepartment of Pediatrics, Medical School, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 484, Minneapolis, MN 55455, USA.
University of Minnesota · USInstitute for Research in Immunology and Cancer · CA

Funding

Translational Pediatric Cancer Epidemiology Research Training GrantT32CA099936 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Logan G. Spector · 2004 to 2026
$5.1M
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1R01NS115438 · NINDS · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, RATNER, NANCY · 2020 to 2024
$2.9M
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancerR01CA228760 · NCI · UNIVERSITY OF MINNESOTA · PI DAVYDOVA, JULIA, YAMAMOTO, MASATO · 2019 to 2023
$1.7M
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic LeukemiaR01CA151845 · NCI · UNIVERSITY OF MINNESOTA · PI FARRAR, MICHAEL ARCHIBALD · 2011 to 2015
$1.5M
Transponson-based screens for genes involved in acute lymphoblastic LeukemiaR01CA154998 · NCI · UNIVERSITY OF MINNESOTA · PI FARRAR, MICHAEL ARCHIBALD · 2011 to 2015
$1.5M
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDACR01CA276480 · NCI · UNIVERSITY OF MINNESOTA · PI MASATO YAMAMOTO · 2023 to 2026
$1.4M
NCI NIH HHS R01 CA151845NCI NIH HHS R01 CA154998NCI NIH HHS R01 CA228760NCI NIH HHS R01 CA276480NCI NIH HHS T32 CA099936NINDS NIH HHS R01 NS115438
6 · The paper itself

Abstract

Oncolytic adenoviruses (Ads) stand out as a promising strategy for the targeted infection and lysis of tumor cells, with well-established clinical utility across various malignancies. This study delves into the therapeutic potential of oncolytic Ads in the context of neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). Specifically, we evaluate conditionally replicative adenoviruses (CRAds) driven by the cyclooxygenase 2 (COX2) promoter, as selective agents against MPNSTs, demonstrating their preferential targeting of MPNST cells compared with non-malignant Schwann cell control. COX2-driven CRAds, particularly those with modified fiber-knobs exhibit superior binding affinity toward MPNST cells and demonstrate efficient and preferential replication and lysis of MPNST cells, with minimal impact on non-malignant control cells.

Indexed as

conditionally replicative adenovirus (CRAd)cyclooxygenase 2 (COX2)malignant peripheral nerve sheath tumor (MPNST)MT: Regular Issueneurofibromatosis type 1 (NF1)oncolytic adenovirus

Identifiers

PMID38595983
PMCPMC10959710
OpenAlexW4392247444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.